Published in Muscle Nerve on April 01, 2007
Myotonic dystrophy. Neurol Clin (2014) 1.08
Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics (2008) 0.96
Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am (2012) 0.93
HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1. Curr Chem Genomics (2010) 0.85
Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve (2015) 0.78
Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1. Muscle Nerve (2010) 0.77
Teaching video neuroimages: trapezius myotonia percussion sign in myotonic dystrophy type 2. Neurology (2013) 0.75
Positive muscle phenomena--diagnosis, pathogenesis and associated disorders. Nat Rev Neurol (2012) 0.75
Techniques and applications of EMG: measuring motor units from structure to function. J Neurol (2012) 0.75
Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach. J Neurol (2017) 0.75
Electromechanical delays during a fatiguing exercise and recovery in patients with myotonic dystrophy type 1. Eur J Appl Physiol (2017) 0.75
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol (2009) 8.42
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med (2008) 4.65
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet (2006) 4.35
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol (2009) 4.27
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 3.21
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr (2009) 2.90
Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol (2009) 2.88
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Gene expression profile of aging in human muscle. Physiol Genomics (2003) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol (2006) 2.02
Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol (2004) 2.00
RNA-dominant diseases. Hum Mol Genet (2006) 2.00
Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol (2007) 1.91
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2006) 1.83
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol (2006) 1.59
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc (2009) 1.54
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 1.46
Excessive daytime somnolence and increased rapid eye movement pressure in myotonic dystrophy. Sleep (2002) 1.45
Computational method for reducing variance with Affymetrix microarrays. BMC Bioinformatics (2002) 1.44
Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol (2010) 1.44
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol (2012) 1.43
Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA (2012) 1.40
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res A Clin Mol Teratol (2006) 1.24
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve (2013) 1.20
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy study. Magn Reson Imaging (2010) 1.14
Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy. J Child Neurol (2010) 1.12
Myotonic syndromes. Curr Opin Neurol (2002) 1.11
Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther (2011) 1.10
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet (2007) 1.09
If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08
Reduced amount of mitochondrial DNA in aged human muscle. J Appl Physiol (1985) (2002) 1.07
Myotonic dystrophy type 2 and related myotonic disorders. J Neurol (2004) 1.07
Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology (2004) 1.06
Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. J Child Neurol (2010) 1.04
Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve (2007) 1.03
Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr (2013) 1.02
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun (2013) 1.01
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther (2012) 1.00
The nondystrophic myotonias. Neurotherapeutics (2007) 1.00
A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol (2011) 0.99
Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem (2012) 0.99
Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97
Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology (2013) 0.97
Reducing levels of toxic RNA with small molecules. ACS Chem Biol (2013) 0.96
Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab (2009) 0.96
Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol (2006) 0.94
Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol (2008) 0.93
Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve (2012) 0.92
Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res (2008) 0.92
Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2013) 0.90
Treatment options for Duchenne muscular dystrophy. Curr Treat Options Neurol (2008) 0.90
Hydroxychloroquine-induced myopathy. J Clin Rheumatol (2010) 0.89